ArticleFrontiers in endocrinology2025
Systems metabolic insights into kaempferol-mediated alleviation of alcoholic fatty liver disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kaempferol Ameliorates Non-Alcoholic Fatty Liver Disease by Targeting TRIM56 to Regulate Lipid Metabolism.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alcoholic fatty liver disease (AFLD) is a significant global health concern caused by chronic and excessive alcohol consumption, leading to hepatic steatosis, inflammation, and metabolic disruption. Currently, there are limited effective therapeutic options. Kaempferol, a dietary flavonoid, has shown potential for regulating oxidative stress and lipid metabolism. Methods: In this study, C57BL/6 mice (n = 12 per group) were assigned to control, ethanol-fed (AFLD), or ethanol plus kaempferol (KPF) groups. The AFLD model was induced using a modified Lieber-DeCarli diet with stepwise ethanol escalation and a final single binge dose. Kaempferol was administered at 20 mg/kg/day by gavage. Serum biochemical markers, liver histology, oxidative stress indices, and untargeted plasma metabolomics were assessed to evaluate KPF's protective effects. Results: Kaempferol-treated mice exhibited significantly reduced alanine aminotransferase (ALT, p < 0.0001) and aspartate aminotransferase (AST, p < 0.05) levels compared to the AFLD group. Histological analysis revealed improved hepatic architecture and reduced lipid droplet accumulation. Kaempferol also enhanced antioxidant capacity, evidenced by reduced malondialdehyde (MDA, p < 0.05). Metabolomic profiling identified multiple altered metabolites associated with glycolysis, amino acid metabolism, and sphingolipid signaling. Discussion: These findings indicate that kaempferol exerts protective effects against AFLD through multi-target regulation of oxidative stress and metabolic pathways. Our study provides systems-level evidence supporting kaempferol as a promising dietary-based intervention for AFLD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.